Non-Hodgkin Lymphoma

Criteria to qualify for study: Drug used in study:
  • DLBCL, Relapsed or Refractory

LYM 120 TG Therapeutics UTX-TGR-205

A Phase 2b Randomized Study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma

Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • Mantle Cell Lymphoma
  • Pathologically confirmed MCL with documentation of either overexpression of cyclin D1 or presence of t(11;14)
  • Up to 5 prior regimens for MCL and must include Anthracycline or Bendamustine containing chemo and Anti-CD20 monoclonal antibody therapy and Ibrutinib
  • ANC > 1000, Plt > 50 , serum creat < 1.5, bili < 1.5

LYM 111 KTE-C19-102 Kite Pharma

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19in subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Criteria to qualify for study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247

Relapsed or Refractory DLBCL

Criteria to qualify for study: Drug used in study:
  • CD-20 + Relapsed or Refractory DLBCL / available tissue from most recent biopsy or must obtain fresh biopsy. Received only frontline CD20-directed immunotherapy with anthracycline or anthracenedione based multi-agent chemo.
  • Achieve SD, PR or CR compared to baseline pre-treatment, following last cycle of frontline treatment / considered eligible for high dose chemo and ASCT.

LYM 123 SGN 19A 003

A randomized, open labeled phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs RICE large B-cell lymphoma (DLBCL) who are candidate for autologous stem cell transplant.